Delivery details + Order by fax
  • PDF: Immediate delivery

Côte d'Ivoire Pharmaceuticals and Healthcare Report Q4
2012

  • Product Code:BMI08579
  • Publication Date:July 2012
  • Publisher:Business Monitor
  • Product Type: Report
  • Pages:42
  • ISBN:2049-0119
Change currency
Add to my wish list > Ask a question about this product > Call now +44 20 8816 8548
Request sample

Request a sample for Côte d'Ivoire Pharmaceuticals and Healthcare Report Q4

Enter the characters you see in the picture below
Captcha

Côte d'Ivoire Pharmaceuticals and Healthcare Report Q4 2012

BMI View: A lack of domestic pharmaceuticals manufacturing facilities means that Côte d'Ivoire continues to depend upon pharmaceutical imports to meet domestic demand, with France, Morocco and Tunisia providing the majority of imported drugs. The government did attempt to boost the healthcare sector, by hosting a pharmacy exhibition in May 2012, and has launched campaigns to encourage Ivoriens to comply with national vaccination and healthcare campaigns. BMI forecasts that healthcare and pharmaceutical expenditure as a percentage of GDP will decline between 2011 and 2016, and that Côte d'Ivoire will not fufill its potential over the medium term. Security concerns persist, as illustrated by the July 2012 attack on a camp of internally displaced citizens. Headline Expenditure Projections

  • Pharmaceuticals: XOF170.3bn (US$360mn) in 2011 to XOF180.8bn (US$369mn) in 2012;
+6.2% in local currency terms and +2.5% in US dollar terms. Historic data revised downwards marginally from Q312 due to new imports data.
  • Healthcare: XOF571.6bn (US$1.21bn) in 2011 to XOF601.7bn (US$1.23bn) in 2012; +5.3% in local currency terms and +1.6% in US dollar terms. Forecast revised downwards slightly from Q312 due to new historic data.
  • Medical Devices: XOF19.25bn (US$41mn) in 2011 to XOF20.66bn (US$42mn) in 2012;
+7.3% in local currency terms and +3.6% in US dollar terms. Forecast revised downwards slightly compared to Q312. Risk/Reward Rating: In Q412, Côte d'Ivoire kept its position in the penultimate rank in BMI's RRRs for the MEA region, although its overall score remains at 28.0 out of 100, significantly below the regional average of 44.2. Côte d'Ivoire only outranks Sudan in the table and is just under 2pp behind Zimbabwe. Key Trends And Developments
  • Health Minister N'Dri Yoman launched a national child polio vaccination programme in May 2012. The WHO and Rotary International have provided funding for the scheme.
  • In June 2012, Health Minister N'Dri Yoman launched an electronic vaccinations card, which the government aims will increase compliance with vaccinations campaigns, as well as a mother and child health card.
  • President Alassane Ouattara met with Chinese private business owners in July 2012, indicating the Ivorian government's intention to increase international investment as a means of boosting economic recovery. Côte d'Ivoire Pharmaceuticals & Healthcare Report Q4 2012
© Business Monitor International Ltd Page 6 BMI Economic View: Côte d'Ivoire continues on its road to economic recovery, and advances towards peace are boosting the confidence of potential investors. Moves such as the President's meetings with representatives from China's business community are a positive development. We are now forecasting real GDP growth of 8.1% in 2012 and sustained growth of between 4% and 5% until 2021. BMI Political View: Violence following Côte d'Ivoire's 2010 election killed over 3,000 people, and following the arrest of former president Laurant Gbagbo, we see many reasons to be positive about the country's political development. While the situation is still fragile - as attacks on a camp of displaced people in July 2012 illustrate - BMI predicts a gradual return to political stability.
  • Executive Summary
  • Pharmaceuticals Risk/Reward Ratings
    • Table: Pharmaceuticals & Healthcare Q412 Risk/Reward Ratings
  • Rewards
  • Risks
  • Côte D'Ivoire - Market Overview
    • Table: Côte d'Ivoire's Millennium Development Goals
  • Regulatory Regime
  • Pharmacovigilance (PV)
  • Industry Forecast Scenario
  • Overall Market Forecast
    • Table: Pharmaceutical Sales Indicators 2008-2016
  • Key Growth Drivers - Industry
    • Table: Healthcare Expenditure Indicators 2008-2016
    • Table: Healthcare Governmental Indicators 2008-2016
    • Table: Healthcare Private Indicators 2008-2016
  • Key Growth Drivers - Macroeconomic
  • Demographic Outlook
  • Côte d'Ivoire's Population By Age Group, 1990-2020 ('000)
  • Côte d'Ivoire's Population By Age Group, 1990-2020 (% of total)
  • Côte d'Ivoire's Key Population Ratios, 1990-2020
  • Côte d'Ivoire's Rural And Urban Population, 1990-2020
  • Glossary
  • BMI Methodology
  • How We Generate Our Pharmaceuticals Industry Forecasts
  • Pharmaceuticals Risk/Reward Ratings Methodology
  • Ratings Overview
    • Table: Pharmaceuticals Risk/Reward Indicators
  • Weighting
    • Table: Weighting Of Components
  • Sources
Ask a question about this product

Ask a question about Côte d'Ivoire Pharmaceuticals and Healthcare Report Q4

Enter the characters you see in the picture below
Captcha